{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:44:32Z","timestamp":1782719072277,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      SSTR-PET is routinely used to select patients with neuroendocrine neoplasms (NEN) for peptide receptor radionuclide therapy (PRRT). As the kidneys are organs at risk, this study evaluated whether renal uptake on pre-therapeutic SSTR-PET\/CT reflects split or global renal function and correlates with renal absorbed dose during [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-TATE therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, 85 NEN patients treated with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-TATE between 2013 and 2023 were included. All underwent SSTR-PET\/CT using [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE, [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE, or [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TOC plus serum kidney function tests and [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAG3 scintigraphy. Renal PET uptake was compared with serum and scintigraphic kidney parameters. In 30 patients, renal absorbed dose was estimated using post-treatment SPECT\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Renal uptake on SSTR-PET\/CT moderately correlated with split renal function assessed by [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAG3 across all tracers, particularly using SUV\n                      <jats:sub>mean<\/jats:sub>\n                      ([\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.462;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010); [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.515;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004); [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TOC (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.546;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004)). No relevant correlation was observed between total renal PET uptake and tubular extraction rate, eGFR, or serum creatinine. Renal PET uptake showed moderate correlations with mean absorbed doses in selected tracer cohorts ([\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE;\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.585;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.076; [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA-TATE;\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.649;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049). A strong negative correlation between TER and absorbed dose was seen only for [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.768;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SSTR-PET\/CT showed moderate potential to estimate pre-therapeutic split renal function and renal absorbed dose. However, global renal function could not be reliably estimated using PET\/CT. Larger studies are warranted to validate PET\/CT-based kidney assessment for individualized PRRT planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07909-z","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:53:14Z","timestamp":1778896394000},"page":"5491-5500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimation of split renal function on PET using the SSTR-targeting radioligands [18F]SiTATE, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC in a theranostic setting"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6862-2196","authenticated-orcid":false,"given":"Maximilian","family":"Tiling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Zahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Ells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz J.","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"B\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"2","key":"7909_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","volume":"58","author":"E Leoncini","year":"2017","unstructured":"Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017;58(2):368\u201379.","journal-title":"Endocrine"},{"issue":"11","key":"7909_CR2","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","volume":"40","author":"H Geijer","year":"2013","unstructured":"Geijer H, Breimer LH. Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40(11):1770\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7909_CR3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588\u2013601.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7909_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/02841860701441848","volume":"46","author":"M Van Essen","year":"2007","unstructured":"Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46(6):723\u201334.","journal-title":"Acta Oncol"},{"issue":"11","key":"7909_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112975","volume":"15","author":"E Merola","year":"2023","unstructured":"Merola E, Grana CM. Peptide receptor radionuclide therapy (PRRT): innovations and improvements. Cancers. 2023;15(11):2975.","journal-title":"Cancers"},{"issue":"3","key":"7909_CR6","doi-asserted-by":"publisher","first-page":"F457","DOI":"10.1152\/ajprenal.2001.280.3.F457","volume":"280","author":"DA Balster","year":"2001","unstructured":"Balster DA, O\u2019Dorisio MS, Summers MA, Turman MA. Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney. Am J Physiol Ren Physiol. 2001;280(3):F457-65.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"5","key":"7909_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","volume":"37","author":"EJ Rolleman","year":"2010","unstructured":"Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010;37(5):1018\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7909_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O\u2019Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7909_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1055\/a-2127-7880","volume":"62","author":"P Rassek","year":"2023","unstructured":"Rassek P, Schafers M, Rahbar K, Backhaus P. [18F]-PSMA-1007-PET for evaluation of kidney function. Nuklearmedizin. 2023;62(4):244\u201351.","journal-title":"Nuklearmedizin"},{"issue":"4","key":"7909_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7909_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00259-004-1702-y","volume":"32","author":"WA Breeman","year":"2005","unstructured":"Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32(4):478\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7909_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/MNM.0000000000000194","volume":"35","author":"RA Werner","year":"2014","unstructured":"Werner RA, Bluemel C, Lapa C, Muegge DO, Kudlich T, Buck AK, et al. Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted? Nucl Med Commun. 2014;35(11):1143\u20139.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"7909_CR13","first-page":"260","volume":"18","author":"B Bubeck","year":"1987","unstructured":"Bubeck B, Brandau W, Eisenhut M, Weidenhammer K, Georgi P. The tubular extraction rate (TER) of 99m Tc-MAG 3: a new quantitative parameter of renal function. Nuc Compact. 1987;18(5):260\u20137.","journal-title":"Nuc Compact"},{"key":"7909_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF00185857","volume":"19","author":"B Bubeck","year":"1992","unstructured":"Bubeck B, Piepenburg R, Grethe U, Ehrig B, Hahn K. A new principle to normalize plasma concentrations allowing single-sample clearance determinations in both children and adults. Eur J Nucl Med. 1992;19:511\u20136.","journal-title":"Eur J Nucl Med"},{"key":"7909_CR15","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"7909_CR16","doi-asserted-by":"crossref","unstructured":"Rudisile S, Gosewisch A, Wenter V, Unterrainer M, B\u00f6ning G, Gildehaus F, et al. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019;19(1):788.","DOI":"10.1186\/s12885-019-6000-y"},{"issue":"5","key":"7909_CR17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763\u20138.","journal-title":"Anesth Analg"},{"issue":"5","key":"7909_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/RLU.0000000000004599","volume":"48","author":"AB Peterson","year":"2023","unstructured":"Peterson AB, Wang C, Wong KK, Frey KA, Muzik O, Schipper MJ, et al. 177Lu-DOTATATE theranostics: predicting renal dosimetry from pretherapy 68Ga-DOTATATE PET and clinical biomarkers. Clin Nucl Med. 2023;48(5):393\u20139.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"7909_CR19","first-page":"1082","volume":"66","author":"A Akhavanallaf","year":"2025","unstructured":"Akhavanallaf A, Lu Z, Peterson AB, Blakkisrud J, Kurkowska S, Yadav S, et al. Can 177Lu-DOTATATE kidney absorbed doses be predicted from pretherapy SSTR PET? Findings from multicenter data. J Nucl Med. 2025;66(7):1082\u201390.","journal-title":"J Nucl Med"},{"issue":"27","key":"7909_CR20","doi-asserted-by":"publisher","first-page":"41233","DOI":"10.18632\/oncotarget.9775","volume":"7","author":"RA Werner","year":"2016","unstructured":"Werner RA, Beykan S, Higuchi T, L\u00fcckerath K, Weich A, Scheurlen M, et al. The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget. 2016;7(27):41233.","journal-title":"Oncotarget"},{"key":"7909_CR21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","volume":"42","author":"J Svensson","year":"2015","unstructured":"Svensson J, Berg G, W\u00e4ngberg B, Larsson M, Forssell-Aronsson E, Bernhardt P. Renal function affects absorbed dose to the kidneys and haematological toxicity during 177 Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging. 2015;42:947\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7909_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1523-1755.2005.00160.x","volume":"67","author":"R Barone","year":"2005","unstructured":"Barone R, Van Der Smissen P, Devuyst O, Beaujean V, Pauwels S, Courtoy PJ, et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int. 2005;67(3):969\u201376.","journal-title":"Kidney Int"},{"key":"7909_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.06.006","volume":"102","author":"L Geenen","year":"2021","unstructured":"Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu] Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol. 2021;102:1\u201311.","journal-title":"Nucl Med Biol"},{"issue":"7","key":"7909_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI procedure standard for somatostatin receptor\u2013based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med. 2019;60(7):937\u201343.","journal-title":"J Nucl Med"},{"issue":"11","key":"7909_CR25","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00259-021-05351-x","volume":"48","author":"L Beyer","year":"2021","unstructured":"Beyer L, Gosewisch A, Lindner S, V\u00f6lter F, Mittlmeier LM, Tiling R, et al. Dosimetry and optimal scan time of [18F] SiTATE-PET\/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2021;48(11):3571\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07909-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:47:39Z","timestamp":1782715659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7909"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07909-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article was modified to correct the statement in the Funding section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients gave written consent for all examinations, and the local ethics committee granted approval for the retrospective scientific analysis (#24-0982).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, and Consent to publish"}},{"value":"LMU reports fees from Novartis (speaker), Telix Pharmaceuticals (consultant), and Astellas Pharma (speaker). RAW reports speaker honoraria from Novartis\/AAA and PentixaPharm, and advisory board work for Novartis\/AAA and Bayer. AH reports compensation for scientific consulting by ABX advanced biochemical compounds. The remaining authors did not report relevant financial or non-financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}